Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-06
2008-05-06
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S122000
Reexamination Certificate
active
11546814
ABSTRACT:
Organic compounds having the structural formula I are provided where the variables have the values described herein and R1and R2join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group.Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4882342 (1989-11-01), Von der Saal et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5414088 (1995-05-01), Von Der Saal et al.
patent: 5585380 (1996-12-01), Bianco et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5801212 (1998-09-01), Okamoto et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5981569 (1999-11-01), App et al.
patent: 6057320 (2000-05-01), Spada et al.
patent: 6258951 (2001-07-01), Lohmann et al.
patent: 6303600 (2001-10-01), Cox et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6313138 (2001-11-01), Fraley et al.
patent: RE37650 (2002-04-01), Myers et al.
patent: 6420382 (2002-07-01), Fraley et al.
patent: 6479512 (2002-11-01), Fraley et al.
patent: 6593344 (2003-07-01), Biedermann et al.
patent: 6605617 (2003-08-01), Renhowe et al.
patent: 6759417 (2004-07-01), Renhowe et al.
patent: 6762194 (2004-07-01), Renhowe et al.
patent: 6774327 (2004-08-01), Wong
patent: 6800760 (2004-10-01), Renhowe et al.
patent: 2002/0103230 (2002-08-01), Renhowe et al.
patent: 2003/0028018 (2003-02-01), Renhowe et al.
patent: 2003/0207883 (2003-11-01), Renhowe et al.
patent: 2004/0002518 (2004-01-01), Renhowe et al.
patent: 2363459 (1975-06-01), None
patent: 3634066 (1986-07-01), None
patent: 0 290 153 (1998-11-01), None
patent: 19841985 (2000-03-01), None
patent: 0290153 (1988-11-01), None
patent: 0 509 717 (1992-04-01), None
patent: 0 508 800 (1992-10-01), None
patent: 0 747 771 (1996-12-01), None
patent: 0 797 376 (1997-09-01), None
patent: 1 086 705 (2001-03-01), None
patent: 6-9952 (1994-01-01), None
patent: 7-43896 (1995-02-01), None
patent: 8-29973 (1996-02-01), None
patent: 63-258903 (1998-10-01), None
patent: WO 92/18483 (1992-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 95/15758 (1995-06-01), None
patent: WO 95/18801 (1995-07-01), None
patent: WO 97/03069 (1997-01-01), None
patent: WO 97/34876 (1997-09-01), None
patent: WO 97/48694 (1997-12-01), None
patent: WO 98/13350 (1998-04-01), None
patent: WO 99/10349 (1999-03-01), None
patent: WO 99/50263 (1999-10-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 00/03990 (2000-01-01), None
patent: WO 00/20400 (2000-04-01), None
patent: WO 00/27379 (2000-05-01), None
patent: WO 2000/58315 (2000-10-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 01/02369 (2001-01-01), None
patent: WO 01/28993 (2001-04-01), None
patent: WO 01/29025 (2001-04-01), None
patent: WO 01/52904 (2001-07-01), None
patent: WO 01/55114 (2001-08-01), None
patent: WO 01/62251 (2001-08-01), None
patent: WO 01/62252 (2001-08-01), None
patent: WO 02/18383 (2002-03-01), None
patent: WO 02/22598 (2002-03-01), None
patent: WO 02/32861 (2002-04-01), None
patent: WO 03/087095 (2003-10-01), None
patent: WO 2004/018419 (2004-03-01), None
patent: WO 2004/030620 (2004-04-01), None
patent: WO 2004/043389 (2004-05-01), None
patent: WO 2004/087153 (2004-10-01), None
patent: WO 2005/046589 (2005-05-01), None
patent: WO 2005/053692 (2005-06-01), None
patent: WO 2006/081445 (2006-08-01), None
U.S. Appl. No. 10/644,055, filed Aug. 2003, Barsanti et al.
U.S. Appl. No. 10/839,793, filed May 2004, Barsanti et al.
U.S. Appl. No. 10/982,543, filed Nov. 2004, Cal et al.
Angiogenesis Foundation, “New Study Shows That Acute Myeloid Leukemia is Angiogenesis-Dependent,” Jan. 4, 2000; www.angio.org
ewsandviews/ archive2000/jan—4—2000.html.
Aprelikova, O., et al., “FLT4, a novel Class III Receptor Tyrosine Kinase in chromosome 5q33-qter1,” Cancer Res., vol. 52, pp. 746-748, Feb. 1, 1992, published by The American Association for Cancer Research, Stanford University Libraries' High Wire Press, California, United States of America.
Carla Heise, et al., “In vivo Preclinical Evaluation of Tyrosine Kinase Inhibitors with Potent Effects on Tumor Angiogenesis, Growth and Metastasis,” Abstract and presentation material for a presentation at the American Association for Cancer Research meeting held in Apr. 2002.
Carmellet, P. et al., “Angiogenesis in Cancer and Other Diseases,”Nature, 407, pp. 249-257 (2000).
Cecil, Textbook of Medicine, 21st Edition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher), Chapter 198, pp. 1060-1074).
Connolly, D., et al., “Human Vascular Permeability Factor,”J. Biol. Chem., vol. 264, pp. 20017-20024, 1989, published by The American Society For Biochemistry and Molecular Biology, Inc., Stanford University Libraries' High Wire Press, California, United States of America.
Connolly, D., et al., “Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis,”J. Clin. Invest., vol. 84, pp. 1470-1478, Nov. 1989, published by The American Society for Clinical Investigation, Inc., Stanford University Libraries' High Wire Press, California; United States of America.
Dankbar, B. et al., “Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma,”Blood, 2000, vol. 5(8), pp. 2630-2636.
Dermer, G. B., “Another Anniversary for the War on Cancer,”Biotechnology, 1994, vol. 12, p. 320.
DeVries, C., et al., “The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science, vol. 255, pp. 989-991, Feb. 21, 1992, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.
European Search Report dated Feb. 28, 2006 for EP 05017665.0.
Ferrara, N., et al., “The Biology of Vascular Endothelial Growth Factor,”Endocrinol. Rev., vol. 18, No. 1, pp. 4-25, 1997, published by The Endocrine Society, Stanford University Libraries' High Wire Press, California, United States of America.
Folkman, J., “Fighting Cancer by Attacking Its Blood Supply,”Scientific American, vol. 275, pp. 150-154, Sep. 1996, published by Scientific American, Inc., New York, New York, United States of America.
Freshney, R. I.,Culture of Animal Cells—A Manual of Basic Technique, 1983, pp. 1-4; published by Alan R. Liss, Inc.
Gruber, G. et al., “Basic Fibroblast Growth Factor is Expressed in CD19/CD11c-Positive Cells in Hairy Cell Leukemia,”Blood, 1999, vol. 94(3), pp. 1077-1085.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,”Science, 1997, vol. 278, pp. 1041-1042.
Hennequin, L. F., et al., Design and Structure—Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors,:J. Med. Chem., vol. 42, No. 26, pp. 5369-5389, 1999; published by American Chemical Society, Washington, D.C.
Hussong, J. W. et al., “Evidence of increased angiogenesis in acute myeloid leukemia,”Blood, 2000, vol. 95(1), pp. 309-313; The American Society of Hematology.
International Search Report for PCT/US2005/005316 dated Nov. 28, 2005.
Kerbel, R. S., “Tumor Angiogenesis: Past, Present and Near Future,”Carcinogenesis, 2000, vol. 21(3), pp. 505-515; Oxford University Press.
Leung, D., et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen,”Science, vol. 246, pp. 1306-1309, Dec. 8, 1989, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.
Lundberg, L. G. et al., “Bone Marrow in Pol
Hammond Mary Ellen Wernette
Machajewski Timothy
Pecchi Sabina
Renhowe Paul A.
Shafer Cynthia
Chiron Corporation
Davis Zinna N.
Kathardekar Vinit
Meara Joseph
LandOfFree
Heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3934864